Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3- methylglutaryl CoA reductase in rats

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 5, 1997, Pages 580-585

  Johnston, Thomas P ^a   Palmer, Warren K ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Hepatic cholesterol; HMG CoA reductase; Hypercholesterolemia; Hyperlipidemia; Pluronic F 127; Poloxamer 407

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MICROSOME ENZYME; P 407; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHOLESTEROL; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MICROSOMES, LIVER; POLOXALENE; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 0030978983     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199705000-00003     Document Type: Article

References (25)

1. Kritchevsky D. Animal models for atherosclerotic research. In: Kritchevsky D, ed. Handbook of experimental pharmacology: hypolipidemic agents. New York: Springer-Verlag, 1975:215-27.
2. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL rabbit): incidence and development of atherosclerosis and xanthoma. Atherosclerosis 1980;36:261-8.
3. Fantappie S, Crestani M, Bosisio E, et al. Plasma lipoproteins and cholesterol metabolism in spontaneously hyperlipidemic rats. Atherosclerosis 1989;76:163-71.
4. Johnston TP, Miller SC. Toxicological evaluation of poloxamers for intramuscular use. J Parenter Sci Technol 1985;39:83-8.
5. Pec EA, Wout Z, Johnston TP. Biological activity of urease formulated in poloxamer 407 following intraperitoneal injection in the rat. J Pharm Sci 1992;81:626-30.
6. Technical data bulletin on Pluronic and Tetronic surfactants, Parsippany, NJ: BASF Corporation, 1989.
7. Pluronic Polyols: toxicity and irritation data. Form No. 3012-767. Parsippany, NJ: BASF Wyandotte Corporation, 1978:1-31.
8. Wout ZM, Pec EA, Maggiore JA, Williams RH, Palicharla P, Johnston TP. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 1992;46:192-200.
9. Li C, Palmer WK, Johnston TP. Disposition of poloxamer 407 in rats following a single intraperitoneal injection assessed using a simplified colorimetric assay. J Pharm Biomed Anal 1996;14:659-65.
10. Schurr PE, Schultz JR, Parkinson TM. Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs. Lipids 1971;7:68-74.
11. Ishikawa T, Fidge N. Changes in the concentration of plasma lipoproteins and apoproteins following the administration of Triton WR-1339 to rats. J Lipid Res 1979;20:254-64.
12. Porter JA, Carter BL, Johnston TP, Palmer WK. Effects of pravastatin on plasma lipid concentrations in poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy 1995;15:92-8.
13. Schmolka IR. Poloxamers in the pharmaceutical industry. In: Tarcha PJ, ed. Polymers for controlled drug delivery. Boca Raton: CRC Press, 1991:189-215.
14. Ma PTS, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370-4.
15. Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG-CoA reductase. Adv Lipid Res 1976;14:1-74.
16. Edwards PA, Lemongello D, Fogelman AM. Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res 1979;20:40-6.
17. Entenman C. General procedures for separating lipid components of tissue. Methods Enzymol 1957;3:301-2.
18. Snedecor GW, Cochran WG. In: Snedecor GW, Cochran WG, eds. Statistical methods. Ames, IA: The Iowa State University Press, 1980:64-79.
19. Kuroda M, Tanzawa K, Tsujita Y, Endo A. Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in Triton WR-1339-induced hyperlipidemia. Biochim Biophys Acta 1977;489: 119-25.
20. Goldfarb S. Rapid stimulation of hepatic HMG-CoA reductase and cholesterol synthesis by Triton WR 1339. Fed Proc 1975;34:662-7.
21. Shefer S, Nguyen LB, Salen G, et al. Differing effects of cholesterol and taurocholate on steady state hepatic HMG-CoA reductase and cholesterol 7α-hydroxylase activities and mRNA levels in the rat. J Lipid Res 1992;33:1193-200.
22. Anderson JM, Dietschy JM. Regulation of sterol synthesis in 16 tissues of rat I: Effect of diurnal light cycling, fasting, stress, manipulations of enterohepatic circulation and administration of chylomicrons and Triton. J Biol Chem 1977;252:3646-51.
23. Friedman M, Byers SO. Mechanism underlying hypercholesterolemia induced by Triton WR 1339. Am J Physiol 1957;190: 439-45.
24. Miura Y, Hisaki H, Fukushima B, Nagai T, Ikeda T. Detergent induced changes in serum lipid composition in rats. Lipids 1989;24: 915-8.
25. Westesen K, Bunjes H, Koch HJ. Phase behavior of Tyloxapol/Triton X100/water mixtures. J Pharm Sci 1995;84:544-50.